Influenza
Conditions
Brief summary
This is a single blinded placebo controlled phase I study, to assess the safety and immunogenicity of co-administration of the candidate influenza vaccine MVA-NP+M1 with seasonal influenza vaccine. All volunteers recruited will be adults aged 50 and over. The rationale behind co-administration of MVA-NP+M1 with a seasonal influenza vaccine (TIV) is that the immune system will be stimulated to produce both influenza specific T cells and influenza specific antibodies.
Interventions
BIOLOGICALTIV and MVA-NP+M1
1.5 x 108 pfu MVA-NP+M1, intramuscular injection into the thigh. Inactivated Influenza Vaccine (Split Virion) 0.5ml (containing 15 micrograms of haemagglutinin, intramuscular injection into the thigh
BIOLOGICALSaline placebo and seasonal influenza vaccine TIV
Saline placebo, intramuscular injection into the thigh. Inactivated Influenza Vaccine (Split Virion) 0.5ml (containing 15 micrograms of haemagglutinin, intramuscular injection into the thigh
Sponsors
University of Oxford
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Men and women aged 50 or over with no upper age limit * Resident in or near Oxford for the duration of the vaccination study * Able and willing (in the Investigators' opinions) to comply with all study requirements * Willing to allow the investigators to discuss the volunteer's medical history with their General Practitioner * For females who are not post-menopausal, a negative pregnancy test on the day of vaccination and agreement to practice effective contraception for the duration of the study * Agreement to refrain from blood donation during the course of the study * Written informed consent
Exclusion criteria
Participation in another research study involving an investigational product in the 30 days preceding enrolment, or planned use during the study period * Receipt of MVA or smallpox vaccines in the last 5 years, or receipt of the 2011/12 seasonal influenza vaccine prior to entering the study. * Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate * Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled/topical steroids are allowed) * History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, e.g. egg products * Any history of anaphylaxis in reaction to vaccination * Recent treatment for cancer (except basal cell carcinoma and cervical carcinoma in situ) * History of serious psychiatric condition * Suspected or known current injecting drug or alcohol abuse (as defined by an alcohol intake of greater than 42 units every week) * Seropositive for hepatitis B surface (HBsAg) or hepatitis C virus (antibodies to HCV) * For pre-menopausal females, pregnancy, lactation or willingness/intention to become pregnant during the study * Any other significant disease, disorder or finding (including blood test results), which, in the opinion of the Investigators, would either put the volunteer at risk because of participation in the study, or may influence the result of the study. * No response / confirmation from GP regarding previous medical history
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety of co-administration of MVA-NP+M1 and seasonal influenza vaccine. | Participants will be followed for the duration of the study, an expected average of 6 months | The specific endpoints for safety and reactogenicity will be actively and passively collected data on adverse events. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Immune response generated by co-administration of MVA-NP+M1 and seasonal influenza vaccine | Participants will be followed for the duration of the study, an expected average of 6 months | To assess immune response generated by co-administration of MVA-NP+M1 by interferon-gamma ELISpot and ELISA. |
Countries
United Kingdom
Outcome results
None listed